Investigating EGR1 signaling pathways in aggressive lymphoma
Official title: Targeting EGR1 signaling pathways in diffuse large B cell lymphoma
Funded at University of Wisconsin-Madison · NIH-10982513 · Data updated 2026-11-12
This study is looking at a tough type of lymphoma called ABC DLBCL to figure out why some treatments don’t work and hopes to find new ways to help patients who haven’t had success with current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | December 20, 2021 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $349,612 |
| NIH project number | 5R01CA266354-04 |
| Project ID | NIH-10982513 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with activated B cell-like diffuse large B cell lymphoma who have experienced treatment resistance.
✕Less likely to help
Patients with other types of lymphoma or those who have not been diagnosed with diffuse large B cell lymphoma may not benefit from this research.
What this research studies
This research focuses on diffuse large B cell lymphoma (DLBCL), particularly the activated B cell-like (ABC) subtype, which is known for its aggressive nature and poor response to current treatments. The study aims to understand the mechanisms behind drug resistance in ABC DLBCL, especially in relation to the EGR1 protein, which plays a crucial role in the survival and proliferation of these cancer cells. By targeting EGR1 and its associated signaling pathways, the research seeks to develop new therapeutic strategies that could improve treatment outcomes for patients who have not responded to existing therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with aggressive forms of lymphoma, potentially improving survival rates.
How similar studies have gone: Previous research has shown promising results in targeting similar signaling pathways in other cancers, suggesting potential for success in this novel approach.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Rui, Lixin — University of Wisconsin-Madison
- Study coordinator: Rui, Lixin
Related research
Other NIH-funded projects on the same topics.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
Lowering c-Myc to treat aggressive large B‑cell lymphoma
This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.